Levodopa and Plant-Derived Compounds in Parkinson's Disease: Understanding Current Treatments and Emerging Natural Therapies

Table of Contents

• Key Points
• Background: Why This Research Matters
• How This Research Was Conducted
• What Happens in the Brain During Parkinson's Disease
• What Causes Parkinson's Disease?
• Plant-Based Bioactive Compounds: The Natural Arsenal
• How Levodopa and Natural Compounds Work
• Clinical Implications: What This Means for Patients
• Study Limitations
• Recommendations for Patients and Researchers
• Frequently Asked Questions
• Source Information

Key Points

• Levodopa remains the most effective treatment for motor symptoms; no natural compound has matched its relief.
• Plant compounds may complement levodopa by reducing oxidative stress, inflammation, and α-synuclein aggregation.
• Most evidence comes from cell and animal studies, not large human trials, so results are not proven.
• Natural supplements face bioavailability, standardization, and interaction risks; always consult your neurologist.
• Berberine may raise brain dopamine by altering gut bacteria, suggesting future gut-brain axis therapies.

Background: Why This Research Matters

Parkinson's disease is the second most common neurodegenerative disorder in the world, affecting millions of people. In Parkinson's disease, the hallmark problem is the degeneration of dopaminergic neurons (nerve cells that produce dopamine) in a brain region called the substantia nigra. This leads to a shortage of dopamine—a chemical messenger essential for smooth, coordinated movement—and results in the classic motor symptoms of the disease: bradykinesia (slowness of movement), rigidity (stiffness), and tremors.

Several classes of medications are currently available to treat Parkinson's disease. These include:

• Levodopa (L-DOPA) — the gold standard treatment, which serves as a precursor that the brain converts into dopamine
• Catechol-O-methyltransferase (COMT) inhibitors — such as entacapone, tolcapone, and opicapone — which prolong levodopa's effectiveness by preventing its breakdown in the body
• Monoamine oxidase-B (MAO-B) inhibitors — such as selegiline, rasagiline, and safinamide — which prevent the breakdown of dopamine in the brain, prolonging its activity and reducing oxidative stress
• Dopamine agonists — such as pramipexole, ropinirole, and rotigotine — which directly stimulate dopamine receptors (D1- and D2-like receptors) in the brain

COMT inhibitors work by blocking the enzyme that breaks down levodopa in the peripheral and central nervous systems. This extends levodopa's half-life and increases the amount of drug that reaches the brain. They are mainly used alongside levodopa to reduce "wearing-off" episodes—periods when the medication's effects fade before the next dose. MAO-B inhibitors are often used in early-stage Parkinson's disease as a standalone therapy or with levodopa in later stages, while dopamine agonists are typically used in younger patients to delay the initiation of levodopa and reduce the risk of dyskinesia. However, dopamine agonists can cause side effects such as impulse control disorders (e.g., compulsive gambling or shopping) and hallucinations.

Long-term use of synthetic L-DOPA is linked to serious complications. For many patients, levodopa becomes less predictable over time, causing motor fluctuations and dyskinesias. Even with these medications, current treatments simply compensate for dopamine loss—they do not stop the underlying degeneration of neurons. This has led scientists to investigate natural compounds that might offer more than just symptom relief.

The urgency of this research is highlighted by striking projections: the global prevalence of Parkinson's disease is expected to rise from about 6.2 million cases in 2015 to roughly 25.2 million by 2050, a 112% increase from 2021 estimates. With an aging population, the impact of Parkinson's disease on individuals, families, and healthcare systems will only grow—making the search for disease-modifying treatments more critical than ever.

How This Research Was Conducted

This article is a systematic review—a rigorous type of research that gathers and analyzes all available evidence on a specific question. The research team searched four major scientific databases: PubMed, Scopus, Google Scholar, and Web of Science. They used a combination of keywords such as "Parkinson's disease," "plant-based bioactive compounds in PD," "phytochemicals in Parkinson's disease," "dopaminergic neuroprotection," "comparison of levodopa and plant-derived compounds," and "recent comparisons of levodopa with plant-derived therapeutics."

The inclusion criteria were carefully defined:

• Studies must be peer-reviewed and published in English in reputable scientific journals
• Studies must focus on the relationship between plant-derived bioactive compounds and Parkinson's disease
• Studies must directly compare levodopa with plant-based compounds in laboratory (in vitro) or animal (in vivo) models, or in clinical trials
• Only studies published between 2023 and March 10, 2025 were included, to ensure the analysis reflects the most current evidence

Both preclinical models (cell cultures and animal studies) and human clinical trials were included. Studies were excluded if they were not directly related to Parkinson's disease, lacked methodological rigor, were non-peer-reviewed articles, conference abstracts, or non-English publications. Studies that did not provide full-text availability or failed to offer a clear comparison between levodopa and plant-based compounds were also removed.

This systematic approach was designed to synthesize high-quality evidence while minimizing bias, giving patients and clinicians a reliable picture of the current state of research.

What Happens in the Brain During Parkinson's Disease

Parkinson's disease is defined by distinct brain changes that occur long before symptoms become noticeable. The two main neuropathological hallmarks are Lewy bodies and dopaminergic neuron degeneration.

Lewy bodies are abnormal clumps of protein that form inside neurons. They are primarily composed of a misfolded protein called α-synuclein. These protein aggregates disrupt the cell's normal protein recycling system (proteostasis), damage mitochondria (the cell's energy producers), and promote neuronal toxicity. Over time, the progressive loss of dopaminergic neurons in the substantia nigra pars compacta leads to dopamine deficiency, which underlies the hallmark motor symptoms of bradykinesia, resting tremor, and rigidity.

But Parkinson's disease is not just a movement disorder. Patients often experience non-motor symptoms as well, including:

• Autonomic disorders (blood pressure regulation, digestion, bladder control)
• Mood disorders (depression, anxiety)
• Cognitive disorders (memory problems, difficulty concentrating)

Neuroinflammation is another critical feature of Parkinson's disease pathology. When microglia (the brain's immune cells) become activated and astrocytes (support cells) become reactive, they release pro-inflammatory cytokines and reactive oxygen species (ROS), which worsen neuronal injury. This creates a vicious cycle of inflammation and degeneration.

Additionally, blood-brain barrier (BBB) dysfunction plays a significant role. The BBB is a protective filter that prevents harmful substances in the blood from entering the brain. In Parkinson's disease, the BBB becomes more permeable, allowing inflammatory molecules to leak into the brain and further fuel neuroinflammation and neuronal vulnerability.

Finally, oxidative stress and mitochondrial dysfunction are central to the disease process. Dopamine itself can undergo auto-oxidation, producing harmful byproducts, and impaired mitophagy pathways (the cell's mechanism for clearing damaged mitochondria)—often due to mutations in genes like PINK1 and PRKN—further contribute to neuronal death. These pathways represent important targets for potential therapies.

What Causes Parkinson's Disease?

Parkinson's disease is a multifactorial disorder—meaning it arises from a complex interaction of genetic, environmental, aging, and dietary factors.

Genetics: Familial (inherited) Parkinson's disease accounts for approximately 5%–10% of all cases. Mutations in genes such as SNCA (the gene for α-synuclein), LRRK2, PINK1, and PRKN are associated with these inherited forms. These genes regulate critical cellular processes including mitochondrial function, autophagy (cellular cleanup), lysosomal activity, proteasomal degradation (protein recycling), cellular stress responses, inflammation, and synaptic homeostasis—all of which contribute to the disease when disrupted.

Sporadic (non-inherited) cases, which make up the majority, commonly involve oxidative stress and chronic neuroinflammation driven by reactive oxygen species, microglial activation, and mitochondrial impairment.

The gut-brain axis: Emerging evidence implicates gut-brain axis dysfunction and microbiome dysbiosis (an unhealthy imbalance of gut bacteria) in Parkinson's disease. Peripheral α-synuclein pathology and intestinal inflammation may propagate neurodegeneration up to the brain via the vagus nerve, which connects the gut to the brain.

Environmental exposures significantly increase Parkinson's disease risk, including:

• Pesticides: rotenone and paraquat
• Heavy metals: manganese, mercury, and lead
• Air pollutants

These toxins contribute to oxidative damage and inflammatory pathways.

Aging remains the most prominent risk factor. As we age, our neurons become more vulnerable due to diminished proteostasis, mitochondrial dysfunction, and reduced blood-brain barrier integrity.

Diet also plays a role. Antioxidant-rich diets such as the Mediterranean diet and diets high in flavonoids are associated with neuroprotection, while diets high in saturated fats, cholesterol, pesticides, and heavy metals may elevate vulnerability to the disease.

Plant-Based Bioactive Compounds: The Natural Arsenal

The review focuses on four major classes of plant-derived chemicals with reported anti-parkinsonian potential: polyphenols, flavonoids, alkaloids, and terpenoids. Here is what the research shows about each class.

Polyphenols: Resveratrol, Curcumin, and EGCG

Polyphenols are a diverse group of naturally occurring compounds known for their strong antioxidant and anti-inflammatory properties. Epidemiological observations suggest that diets rich in polyphenols—such as berries, tea, and red wine—are associated with reduced Parkinson's disease risk.

Resveratrol (found in grapes and red wine) has been shown in studies to activate the SIRT1 pathway, improve mitochondrial function, and reduce α-synuclein aggregation. It protects neurons by scavenging reactive oxygen species and activating cellular defense enzymes.

Curcumin (derived from the spice turmeric, Curcuma longa) inhibits oxidative stress, enhances levels of brain-derived neurotrophic factor (BDNF)—a protein that supports neuron survival and growth—and mitigates inflammation in Parkinson's disease models.

EGCG (epigallocatechin-3-gallate), a polyphenol found in green tea, protects dopaminergic neurons by reducing oxidative stress and inhibiting neuroinflammation.

Flavonoids: Quercetin, Apigenin, Naringenin, and Fisetin

Flavonoids are a subclass of polyphenols abundant in fruits and vegetables. In epidemiological studies, higher flavonoid intake has been linked to a lower incidence of Parkinson's disease and slower disease progression.

One notable finding: small clinical trials using flavonoid-rich foods like cocoa or licorice showed modest motor improvements in Parkinson's disease patients. Specific flavonoids with neuroprotective effects include:

• Quercetin (found in apples, onions, and tea): exhibits neuroprotective effects in toxin-induced Parkinson's disease models by reducing oxidative stress, particularly in the cerebellum
• Apigenin (from parsley and chamomile): has notable anti-inflammatory properties and promotes neuronal survival
• Naringenin (from citrus fruits): improves mitochondrial function and can increase dopamine levels in models
• Fisetin (primarily found in strawberries, apples, and persimmons): provides powerful antioxidant and anti-inflammatory effects. It scavenges reactive oxygen species, inhibits pro-inflammatory cytokines, and promotes neuronal survival pathways. Fisetin also helps by chelating metal ions—reducing metal-catalyzed lipid peroxidation and protein aggregation, which are major contributors to neurodegeneration

Alkaloids: Berberine, Caffeine, and Mucuna Pruriens

Plant alkaloids with potential benefits in Parkinson's disease include berberine, caffeine, nicotine, and—importantly—natural L-DOPA derived from the velvet bean.

• Berberine (from Berberis species) is an isoquinoline alkaloid with broad neuroprotective mechanisms. It acts as an antioxidant, anti-apoptotic, and anti-inflammatory agent. Oral berberine can elevate brain dopamine levels and improve motor function in Parkinson's disease model animals, partly by altering the gut microbiome. It also modulates autophagy and mitochondrial function, reducing dopaminergic neuron loss.
• Caffeine (a xanthine alkaloid found in coffee and tea) is epidemiologically linked to lower Parkinson's disease risk. It acts as an adenosine A2A receptor antagonist, which may indirectly support dopaminergic signaling in the brain.
• Mucuna pruriens (velvet bean) deserves special attention. Its seeds naturally contain L-DOPA—the same molecule as synthetic levodopa—along with other alkaloids. It has been used in traditional Ayurvedic medicine for parkinsonian symptoms and is now being re-investigated in modern research.

Terpenoids: Carnosic Acid, Ginkgolide B, and Celastrol

Terpenoids (isoprene-based compounds) from various herbs have shown neuroprotective effects in Parkinson's disease models:

• Carnosic acid (a diterpene from rosemary) enhances endogenous antioxidant pathways in neurons via Nrf2 activation (a protein that regulates antioxidant gene expression) and increases neurotrophic factors like BDNF
• Ginkgolide B (a diterpene from Ginkgo biloba) protects dopaminergic cells by reducing intracellular calcium overload and caspase-3 activity (an enzyme involved in cell death), and by restoring levels of calbindin—a calcium-binding protein that aids neuronal survival. It also shields neurons from oxidative damage and reduces neuroinflammation
• Celastrol (a triterpene from the Tripterygium vine) suppresses neuroinflammation by inhibiting NF-κB signaling, thereby reducing pro-inflammatory cytokines and even toxic α-synuclein species

Post-2022 research has also explored novel combinations. For example, one 2023 study proposed a curcumin-levodopa nanoparticle formulation—a tiny particle combining both compounds—to harness curcumin's neuroprotective effects alongside dopamine replacement therapy, potentially reducing levodopa-induced toxicity.

How Levodopa and Natural Compounds Work

Dopaminergic Pathways: Restoring vs. Protecting

Levodopa's primary mechanism is straightforward: as the metabolic precursor to dopamine, it crosses the blood-brain barrier and is converted into dopamine, replenishing the neurotransmitter that is deficient in Parkinson's disease. This leads to significant relief of motor symptoms.

However—and this is a critical distinction—levodopa mainly addresses dopamine replacement. It does not directly intervene in the degenerative process. It is well documented that conventional dopaminergic drugs provide symptomatic benefit but do not halt or slow the ongoing loss of nigral neurons.

By contrast, most plant-based compounds do not directly increase brain dopamine levels—with one notable exception being Mucuna pruriens, which delivers natural L-DOPA. Instead, natural bioactives tend to modulate dopaminergic pathways indirectly or preserve dopaminergic neurons.

For example, caffeine's antagonism of adenosine A2A receptors in the striatum (a brain region involved in movement control) can enhance dopaminergic signaling and has been associated with lower Parkinson's disease incidence. Berberine, while not a dopamine precursor, was shown in one study to increase striatal dopamine in Parkinson's disease model mice by altering gut microbiota composition—increasing certain gut bacteria that produce dopamine or support host dopamine levels.

Oxidative Stress: A Key Difference

Oxidative damage is a key contributor to Parkinson's disease pathology, and this is where natural compounds markedly differ from levodopa.

Levodopa itself does little to combat oxidative stress—in fact, the oxidative metabolism of dopamine (and of levodopa in peripheral tissues) can generate reactive oxygen species and toxic dopamine-quinones. There is evidence that the oxidation of L-DOPA can produce free radicals that may exacerbate neuronal degeneration.

Natural antioxidants, on the other hand, directly counteract oxidative stress. Polyphenols and flavonoids are well-known free radical scavengers and also boost the body's own antioxidant defenses. Specifically:

• Resveratrol, quercetin, and apigenin have been reported to neutralize reactive oxygen species and upregulate protective antioxidant enzymes like superoxide dismutase (SOD) and heme oxygenase-1 (HO-1) in cellular Parkinson's disease models
• Terpenoids like ginkgolide B and celastrol promote the survival of dopaminergic neurons by modulating cell-death pathways. Ginkgolide B reduces calcium-mediated cytotoxicity and caspase-3 activation, helping prevent apoptosis (programmed cell death) of dopaminergic cells
• Resveratrol has been shown to lower active caspase-3 levels and prevent neuronal death

This fundamental difference in mechanism—symptomatic dopamine replacement versus active neuroprotection—is the reason plant-derived compounds are increasingly viewed as potentially valuable partners to levodopa rather than replacements for it.

Clinical Implications: What This Means for Patients

The findings of this review carry several important implications for people living with Parkinson's disease.

First, levodopa remains indispensable—no plant compound has yet demonstrated the same level of symptom relief. Patients should not view natural products as a substitute for their prescribed medication.

Second, the concept of adjunct therapy is gaining traction. Certain phytochemicals—such as curcumin, resveratrol, and quercetin—have demonstrated synergistic effects when combined with levodopa in laboratory models. These combinations may enhance motor function, reduce levodopa-induced toxicity, and prolong its therapeutic efficacy, potentially improving quality of life for patients.

Third, natural compounds offer something levodopa cannot: disease-modifying potential. By reducing oxidative stress, blocking neuroinflammation, preventing α-synuclein aggregation, and protecting mitochondria, these compounds may slow the underlying progression of the disease—not just mask its symptoms.

Fourth, there is the exciting possibility of targeting non-dopaminergic pathways. Many plant compounds act through mechanisms unrelated to dopamine, such as the SIRT1 pathway, Nrf2 activation, NF-κB inhibition, and modulation of the gut microbiome. This opens up entirely new avenues for treatment that go beyond the dopamine-centric approach of current therapies.

Finally, the gut-brain axis represents a particularly interesting frontier. The finding that berberine can increase brain dopamine by altering gut bacteria suggests that dietary interventions or probiotic strategies might one day play a role in Parkinson's disease management.

Study Limitations

While the findings are promising, it is important to understand what this study could not prove. Most of the evidence comes from preclinical studies—cell cultures and animal models—not from large-scale human clinical trials. Results that work in a lab dish or in a mouse may not translate to the same effects in humans.

The review also highlights significant challenges that remain:

• Bioavailability: Many plant compounds are poorly absorbed by the body and have difficulty crossing the blood-brain barrier in sufficient quantities. The 2023 curcumin-levodopa nanoparticle formulation is one attempt to address this, but much more work is needed
• Standardization: Unlike pharmaceutical drugs, which are produced with precise quality control, plant extracts vary in their composition depending on the source, growing conditions, and extraction methods. Standardized formulations are needed before these can be used reliably in clinical practice
• Lack of long-term trials: The studies reviewed were published between 2023 and 2025, meaning the follow-up periods are still short. Long-term clinical trials are needed to evaluate safety, efficacy, and disease-modifying effects over many years
• Direct comparisons are limited: The inclusion criteria required direct comparisons between levodopa and plant-based compounds, which many studies do not provide

Recommendations for Patients and Researchers

Based on this review, here is practical guidance for patients and the scientific community.

For patients:

1. Never stop or reduce levodopa without consulting your neurologist. Levodopa remains the most effective treatment for motor symptoms, and abruptly changing medication can cause serious complications
2. Talk to your doctor about the potential risks and benefits of any natural supplements. Some plant compounds can interact with prescription medications
3. Consider a diet rich in polyphenols and flavonoids—such as berries, tea, red wine (in moderation), apples, onions, citrus fruits, strawberries, and green tea. While dietary changes cannot cure Parkinson's disease, the epidemiological evidence suggests these foods are associated with a lower risk and slower progression
4. Be cautious about supplements. Because of poor bioavailability, many oral supplements may not deliver enough of the active compound to the brain to be effective. There are also no standardized formulations yet, so the content of supplements varies widely between brands
5. Stay informed. Research in this area is moving rapidly, and new clinical trials are being launched

For researchers:

1. Prioritize improving bioavailability of plant compounds through nanoparticle formulations, prodrugs, or novel delivery systems
2. Develop standardized formulations so that results can be reliably reproduced across studies
3. Conduct long-term clinical trials comparing plant-derived compounds in combination with levodopa versus levodopa alone
4. Investigate the gut-brain axis as a therapeutic target—the berberine findings suggest this is a promising direction
5. Explore combination therapies that simultaneously target multiple pathways: oxidative stress, neuroinflammation, α-synuclein aggregation, and mitochondrial dysfunction

The road from promising laboratory findings to approved treatments is long, but the potential payoff is enormous: a therapy that not only manages symptoms but actually slows the progression of Parkinson's disease.

Frequently Asked Questions

Can natural compounds like curcumin or resveratrol replace levodopa?

No. Levodopa is indispensable and natural compounds are not replacements. Most plant compounds do not directly increase brain dopamine levels, with the exception of Mucuna pruriens, which contains natural L-DOPA. In laboratory models, some phytochemicals have shown synergistic effects when combined with levodopa, but they have not matched levodopa's symptom relief.

What are the main complications of long-term levodopa use?

Long-term levodopa use can become less predictable over time, causing motor fluctuations, dyskinesias (involuntary movements), and oxidative stress. Levodopa mainly replaces dopamine and does not stop underlying neuron degeneration. The review notes that oxidation of L-DOPA can produce free radicals that may worsen neuronal damage, which is why adjunct natural therapies are being studied.

How might plant-derived compounds help Parkinson's disease patients alongside levodopa?

Natural compounds such as curcumin, resveratrol, quercetin, berberine, and ginkgolide B may offer neuroprotective effects by reducing oxidative stress, blocking neuroinflammation, preventing α-synuclein aggregation, and protecting mitochondria. These actions target underlying disease processes rather than just replacing dopamine, potentially slowing disease progression and reducing levodopa-induced toxicity, though more research is needed.

What is the gut-brain axis and how does it relate to Parkinson's treatment?

The gut-brain axis involves communication between the gut and brain, and gut microbiome imbalance may contribute to Parkinson's disease. In one study, berberine increased brain dopamine in Parkinson's model mice by altering gut bacteria that support dopamine levels. This suggests dietary interventions or probiotic strategies might one day play a role in management, but this remains experimental.

Are there any risks or limitations with using natural supplements for Parkinson's?

Yes. Many plant compounds are poorly absorbed and may not cross the blood-brain barrier in sufficient amounts. Supplements vary widely in composition and lack standardized formulations. They can interact with prescription medications. Always consult your doctor before taking any supplement, and do not stop or reduce levodopa without medical guidance.

Can eating foods rich in polyphenols and flavonoids slow Parkinson's progression?

Epidemiological evidence suggests diets rich in polyphenols and flavonoids—such as berries, tea, red wine in moderation, apples, onions, citrus fruits, strawberries, and green tea—are associated with lower Parkinson's risk and slower progression. However, dietary changes cannot cure the disease, and supplements may not deliver enough active compound to the brain due to poor bioavailability.

I have Parkinson’s and take levodopa. Should I get a second opinion before adding plant-derived supplements like curcumin or resveratrol?

A second opinion can help you evaluate whether adding plant-derived compounds such as curcumin, resveratrol, or quercetin to your prescribed levodopa is appropriate. These natural compounds are not proven replacements for levodopa, which remains the most effective motor-symptom treatment. Most evidence comes from laboratory and animal studies, not large human trials, and many supplements have poor bioavailability. Since some plant compounds can interact with medications, a second opinion can clarify risks and benefits before you change your regimen. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Levodopa and Plant-Derived Bioactive Compounds in Parkinson's Disease: Mechanisms, Efficacy, and Future Perspectives.

Authors: Aktaş E, Hanağası HA, Özgentürk NÖ.

Journal: CNS Neuroscience & Therapeutics, 2025; 31:e70540

Publication details: Published by John Wiley & Sons Ltd. Received March 31, 2025; Revised July 10, 2025; Accepted July 21, 2025. Open access under the Creative Commons Attribution License.

Affiliations: Faculty of Art and Science, Molecular Biology and Genetics, Yıldız Technical University, Istanbul, Turkey; Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Note: This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not constitute medical advice. Always consult your healthcare provider before making any changes to your treatment plan.